AbCellera Biologics Inc. ABCL Increase Decrease In Receivables
Increase Decrease In Receivables at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s increase decrease in receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s increase decrease in receivables?
- AbCellera Biologics Inc. (ABCL) reported increase decrease in receivables of -$13.1M in Q1 2026.
- How has AbCellera Biologics Inc.'s increase decrease in receivables changed year-over-year?
- AbCellera Biologics Inc.'s increase decrease in receivables decreased by 1256.5% year-over-year, from $1.13M to -$13.1M.
- What is the long-term trend for AbCellera Biologics Inc.'s increase decrease in receivables?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s increase decrease in receivables has grown at a 10.0% compound annual growth rate (CAGR), from $45.93M to $55.62M.
- What does increase decrease in receivables mean?
- This measures the net change in amounts owed to the company by customers for goods or services delivered, indicating the efficiency of the cash collection cycle. An increase in receivables relative to revenue may suggest longer payment terms or potential difficulties in collecting cash from partners. It is a key indicator of working capital management and liquidity health.